Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Molecular Imaging and Biology

01-11-2008 | Editorial

Quantitative Imaging Biomarkers Alliance FDG–PET/CT Working Group Report

Author: Richard Frank

Published in: Molecular Imaging and Biology | Issue 6/2008

Login to get access

Excerpt

(FDG–PET/CT) convened working groups of the Quantitative Imaging The Radiological Society of North America (RSNA) Biomarkers Alliance (QIBA) chaired by Daniel Sullivan, MD (RSNA Science Advisor) to plan the adoption of hardware and software standards to improve accuracy and reproducibility of quantitative results from imaging biomarkers in multicenter clinical trials. 2-Deoxy-2-[18F]fluoro-d-glucose-positron emission tomography/computed tomography (FDG–PET/CT), dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), and volumetric computed tomography (vCT) to quantify longitudinally the effects of novel therapeutic candidates for cancer are the imaging biomarkers initially chosen for QIBA to focus on. The mission of QIBA is helping to transform radiology from a qualitative to a more quantitative science by helping patients benefit from accelerated development and dissemination of new pharmacologic, biologic, and interventional diagnosis and treatment approaches. …
Literature
1.
Hallett WA, Maguire RP, McCarthy TJ, Schmidt ME, Young H (2007) Considerations for generic oncology FDG-PET/CT protocol preparation in drug development. IDrugs 10(11):791–796, NovPubMed
2.
Hillner BE, Siegel BA, Liu D, Shields AF, Gareen IF, Hanna L, Stine SH, Coleman RE (2008) Impact of positron emission tomography/computed tomography and positron emission tomography (PET) alone on expected management of patients with cancer: initial results from the National Oncologic PET Registry. J Clin Oncol 26(13):2155–2161, Epub 2008 Mar 24, May 1PubMedCrossRef
3.
Hoekstra CJ, Paglianiti I, Hoekstra OS, Smit EF, Postmus PE, Teule GJJ, Lammertsma AA (2000) Monitoring response to therapy in cancer using [18F]-2-fluoro-2-deoxy-D-glucose and positron emission tomography: an overview of different analytical methods. Eur J Nucl Med 27:731–743PubMedCrossRef
4.
Kinahan P, Christian P, Karp J, Chaitanya D, Zubal G, Pappas V, McEwan A (2007) A calibration phantom for multi-center PET/CT studies of assessing response to therapy. J Nucl Med 48(Supplement 2):194P
5.
Kinahan P, Doot R, Christian P, Karp J, Scheuermann J, Zimmerman R, Saffer J, McEwan A (2008) Multi-center comparison of a PET/CT calibration phantom for imaging trials. J Nucl Med 49(Supplement 1):63P
6.
Minn H, Zasadny KR, Quint LE, Wahl RL (1995) Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-D-glucose uptake at PET. Radiology 196:167–173PubMed
7.
Weber WA, Ziegler SI, Thodtmann R, Hanauske A, Schwaiger M (1999) Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40:1771–1777PubMed
Metadata
Title
Quantitative Imaging Biomarkers Alliance FDG–PET/CT Working Group Report
Author
Richard Frank
Publication date
01-11-2008
Publisher
Springer-Verlag
Published in
Molecular Imaging and Biology / Issue 6/2008
Print ISSN: 1536-1632
Electronic ISSN: 1860-2002
DOI
https://doi.org/10.1007/s11307-008-0167-y